Working... Menu

A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00831649
Recruitment Status : Terminated (The biological effect seen with natalizumab was not sufficient to warrant further development in RA.)
First Posted : January 29, 2009
Last Update Posted : June 16, 2016
Elan Pharmaceuticals
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of natalizumab in subjects with active rheumatoid arthritis (RA) receiving concomitant methotrexate (MTX)

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Drug: natalizumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201
Study Start Date : September 2004
Actual Primary Completion Date : February 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Natalizumab

Arm Intervention/treatment
Experimental: natalizumab Drug: natalizumab
Other Name: TYSABRI

Primary Outcome Measures :
  1. The number and proportion of subjects with AEs
  2. The number and proportion of subjects with SAEs
  3. The number and percentage of subjects who discontinue early from the study due to an AE
  4. Assessment of clinical laboratory parameters, physical examination, and vital signs.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


Subjects will be eligible to begin study participation if they meet all of the following inclusion criteria:

  • Subjects must give written informed consent
  • Male or female subjects ≥18 to ≤75 years of age (at randomization in Study ELN100226-RA201)
  • Subjects must have been randomized in Study ELN100226-RA201;
  • Subjects who have completed the Month 6 visit of Study ELN100226-RA201 OR Subjects who have an inadequate therapeutic response (defined as a < 20% reduction from baseline [Month 0 in Study ELN100226-RA201] for both painful/tender and swollen joint counts) after receiving at least 4 infusions of study drug and has not been rescued with other RA medications during the treatment phase of Study ELN100226-RA201;
  • Subjects must be taking MTX at the same dose last used in Study ELN100226-RA201;
  • Female subjects of childbearing potential agreed to use adequate, contraceptive methods (either intrauterine device [IUD], oral or depot contraceptive, or barrier plus spermicide). Female subjects of childbearing potential used adequate contraception for at least 2 months prior to study entry and continued contraception for at least 3 months after their last infusion of study drug;
  • Subjects must be willing and able to complete all planned study procedures.


Subjects will be excluded from the study if they meet any of the following exclusion criteria:

  • Females who are pregnant or breastfeeding or those planning to become pregnant in the next 14 months;
  • Subjects who have experienced anaphylaxis, angioedema, urticaria, clinical syndrome diagnostic of serum sickness, or biopsy-proven vasculitis to a previous infusion of study drug;
  • Subjects who received rescue intervention in Study ELN100226-RA201, defined as an increase in dose of an existing permitted concomitant treatment of RA or the introduction of a new treatment of RA;
  • Subject who are expected to be unavailable for the duration of the trial, likely to be noncompliant with the Protocol, or who are felt to be unsuitable by the Investigator for any other reason;
  • Subjects with a history of a malignancy (other than surgically excised basal or squamous cell carcinoma of the skin);
  • Subjects with a history of clinically significant and/or persistent gastrointestinal, pulmonary, chronic infection, cardiovascular, renal, hepatic, neurological, dermatological, immunological, major psychiatric (including drug or alcohol abusers) or hematological illness, which in the opinion of the Investigator places the subject at unacceptable risk for participation in the study;
  • Subjects who intend to donate blood or blood products during the period of the study or within one month following completion of the study.

Layout table for additonal information
Responsible Party: Biogen Identifier: NCT00831649     History of Changes
Other Study ID Numbers: ELN100226-RA251
First Posted: January 29, 2009    Key Record Dates
Last Update Posted: June 16, 2016
Last Verified: January 2009

Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs